Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2020-08-10 09:25 am Sale | 13G | AGIOS PHARMACEUTICALS INC AGIO | FMR LLC | 4,542,806 6.573% | -4,285,656 (-48.54%) | View |
2020-02-14 2:35 pm Purchase | 13G | AGIOS PHARMACEUTICALS INC AGIO | BB BIOTECH AG | 3,896,954 5.7% | 918,820 (+30.85%) | View |
2020-02-14 12:07 pm Purchase | 13G | AGIOS PHARMACEUTICALS INC AGIO | Capital International Investors | 4,649,474 6.9% | 611,930 (+15.16%) | View |
2020-02-12 09:23 am Purchase | 13G | AGIOS PHARMACEUTICALS INC AGIO | VANGUARD GROUP INC | 5,606,855 8.2% | 984,906 (+21.31%) | View |
2020-02-12 07:23 am Sale | 13G | AGIOS PHARMACEUTICALS INC AGIO | VANGUARD SPECIALIZED FUNDS | 0 0% | -4,402,124 (Position Closed) | View |
2020-02-07 11:12 am Purchase | 13G | AGIOS PHARMACEUTICALS INC AGIO | FMR LLC | 8,828,462 12.913% | 101,661 (+1.16%) | View |
2020-02-07 08:45 am Purchase | 13G | AGIOS PHARMACEUTICALS INC AGIO | BlackRock Inc. BLK | 3,893,394 5.8% | 980,611 (+33.67%) | View |
2020-01-08 2:01 pm Sale | 13G | AGIOS PHARMACEUTICALS INC AGIO | WELLINGTON MANAGEMENT GROUP LLP | 7,975,823 11.67% | -167,293 (-2.05%) | View |
2019-11-14 4:07 pm Purchase | 13D | AGIOS PHARMACEUTICALS INC AGIO | Celgene European Investment Co LLC | 7,121,658 10.6% | 403,225 (+6.00%) | View |
2019-10-09 4:20 pm Sale | 13G | AGIOS PHARMACEUTICALS INC AGIO | BlackRock Inc. BLK | 2,912,783 4.96% | -411,696 (-12.38%) | View |